Gosho M, Nagashima K, Sato Y. Study designs and statistical analyses for biomarker research. Sensors (Basel, Switzerland). 2012;12(7):8966–86. doi: 10.3390/s120708966. View Article PubMed/NCBI Google Scholar

Lee JJ, Xuemin G, Suyu L. Bayesian adaptive randomization designs for targeted agent development. Clinical trials (London, England). 2010;7(5):584–96. doi: 10.1177/1740774510373120. View Article PubMed/NCBI Google Scholar

Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. Journal of clinical oncology: official journalof the American Society of Clinical Oncology. 2009;27(24):4027–34. doi: 10.1200/JCO.2009.22.3701. View Article PubMed/NCBI Google Scholar

Kelloff GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right patient. Nature reviews Drug discovery. 2012;11(3):201–14. doi: 10.1038/nrd3651. pmid:22322254 View Article PubMed/NCBI Google Scholar

Chow S-C, Tu Y-H. On Two-stage Seamless Adaptive Design in Clinical Trials. Journal of the Formosan Medical Association = Taiwan yi zhi. 2008;107(12 Suppl):52–60. pmid:19129046 View Article PubMed/NCBI Google Scholar

Chow S-C, Chang M. Adaptive design methods in clinical trials—a review. Orphanet journal of rare diseases. 2008;3:11-. doi: 10.1186/1750-1172-3-11. pmid:18454853 View Article PubMed/NCBI Google Scholar

Freidlin B, Korn EL. Biomarker-adaptive clinical trial designs. Pharmacogenomics. 2010;11(12):1679–82. doi: 10.2217/pgs.10.153. pmid:21142910 View Article PubMed/NCBI Google Scholar

Galanis E, Wu W, Sarkaria J, Chang SM, Colman H, Sargent D, et al. Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments. Current oncology reports. 2011;13(1):42–9. doi: 10.1007/s11912-010-0144-x. pmid:21125354 View Article PubMed/NCBI Google Scholar

Ang M-K, Tan S-B, Lim W-T. Phase II clinical trials in oncology: are we hitting the target? Expert review of anticancer therapy. 2010;10(3):427–38. doi: 10.1586/era.09.178. pmid:20214523 View Article PubMed/NCBI Google Scholar

Berry DA. Bayesian clinical trials. Nature reviews Drug discovery. 2006;5(1):27–36. doi: 10.1038/nrd1927. pmid:16485344 View Article PubMed/NCBI Google Scholar

Scher HI, Nasso SF, Rubin EH, Simon R. Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011;17(21):6634–40. doi: 10.1158/1078-0432.CCR-11-1105. View Article  PubMed/NCBI Google Scholar

Berry DA, Herbst RS, Rubin EH. Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012;18(3):638–44. doi: 10.1158/1078-0432.CCR-11-2018. View Article PubMed/NCBI Google Scholar

Tajik P, Zwinderman AH, Mol BW, Bossuyt PM. Trial designs for personalizing cancer care: a systematic review and classification. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013;19(17):4578–88. doi: 10.1158/1078-0432.CCR-12-3722. View Article PubMed/NCBI  Google Scholar

Di Maio M, Gallo C, De Maio E, Morabito A, Piccirillo MC, Gridelli C, et al. Methodological aspects of lung cancer clinical trials in the era of targeted agents. Lung cancer (Amsterdam, Netherlands). 2010;67(2):127–35. doi: 10.1016/j.lungcan.2009.10.001.  View Article PubMed/NCBI Google Scholar

Wason JMS, Trippa L. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. Statistics in medicine. 2014;33(13):2206–21. doi: 10.1002/sim.6086. pmid:24421053 View Article PubMed/NCBI Google Scholar

Sato Y, Laird NM, Yoshida T. Biostatistic tools in pharmacogenomics—advances, challenges, potential. Current pharmaceutical design. 2010;16(20):2232–40. pmid:20459388 View Article PubMed/NCBI Google Scholar

Korn EL, Freidlin B. Outcome—adaptive randomization: is it useful? Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011;29(6):771–6. doi: 10.1200/JCO.2010.31.1423. View Article PubMed/NCBI Google Scholar

Lai TL, Lavori PW, Shih M-CI, Sikic BI. Clinical trial designs for testing biomarker-based personalized therapies. Clinical trials (London, England). 2012;9(2):141–54. doi: 10.1177/1740774512437252. View Article PubMed/NCBI Google Scholar

Gold KA, Kim ES, Lee JJ, Wistuba II, Farhangfar CJ, Hong WK. The BATTLE to personalize lung cancer prevention through reverse migration. Cancer prevention research (Philadelphia, Pa). 2011;4(7):962–72. doi: 10.1158/1940-6207.CAPR-11-0232. View Article PubMed/NCBI Google Scholar

Lai TL, Liao OY-W, Kim DW. Group sequential designs for developing and testing biomarker-guided personalized therapies in comparative effectiveness research. Contemporary clinical trials. 2013;36(2):651–63. doi: 10.1016/j.cct.2013.08.007. pmid:23994669 View Article PubMed/NCBI Google Scholar

Younes A, Berry DA. From drug discovery to biomarker-driven clinical trials in lymphoma. Nature reviews Clinical oncology. 2012;9(11):643–53. doi: 10.1038/nrclinonc.2012.156. pmid:22965151 View Article PubMed/NCB Google Scholar

Buyse M, Michiels S, Sargent DJ, Grothey A, Matheson A, de Gramont A. Integrating biomarkers in clinical trials. Expert review of molecular diagnostics. 2011;11(2):171–82. doi: 10.1586/erm.10.120. pmid:21405968 View Article PubMed/NCBI Google Scholar

Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer—a step toward personalized medicine. Clinical trials (London, England). 2008;5(3):181–93. doi: 10.1177/1740774508091815. View Article PubMed/NCBI Google Scholar

European Medicines Agency. Reflection paper on methodological issues associated with pharmacogenomic biomarkers in relation to clinical development and patient selection London; 2011 [updated [cited 2012 Jul 3]; cited 2015 10 Oct]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/07/WC500108672.pdf.

Liu A, Liu C, Li Q, Yu KF, Yuan VW. A threshold sample-enrichment approach in a clinical trial with heterogeneous subpopulations. Clinical trials (London, England). 2010;7(5):537–45. doi: 10.1177/1740774510378695. View Article PubMed/NCBI Google Scholar